Date:8/21/2008

ents by using words such as "expect," "anticipate," "estimate," "plan," "will," "would," "forecast," "believe," "guidance," "projection" or similar expressions, but these words are not the exclusive means for identifying such statements. The Company cautions that a number of risks, uncertainties, and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, risks associated with the Company's continued research and development efforts with respect to the endovascular products (including the risk that those efforts will not be successful and that some or all of the associated milestone payments will not be received) and Spectranetics' success in selling the ThromCat and SafeCross products, as well as competition from other technologies, the Company's success in distributing its products into the marketplace, the Company's dependence on four major customers (St. Jude Medical, Arthrex, Orthovita and Spectranetics) and their success in selling Kensey Nash related products in the marketplace, the impact of product recalls and other manufacturing issues, and competition from other technologies. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's SEC filings, including the disclosure under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

- FINANCIAL INFORMATION TO FOLLOW -

KENSEY NASH CORPORATION

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(Unaudited)

Three Months Fiscal Year

'/>"/>

SOURCE Kensey Nash Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Related biology technology :

1. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
2. Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
3. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
4. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
5. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
6. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
7. InstaCare Corp. Continues Turnaround & Reports 291% Revenues Increase in 2Q 2008
8. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
9. Expert Neurology Panel Weighs Impact of New Reports of PML in Multiple Sclerosis Patients on Tysabri
10. Arpida Reports Interim Results for Six Months to 30 June 2008
11. Rosetta Genomics Reports Second Quarter 2008 Financial Results